Karamvir Yadav, Medical Oncologist in Jaipur, India, shared a post on X:
“Can anti-angiogenic therapy enhance immunotherapy in NSCLC?
The CAMPASS phase III trial suggests yes.
Benmelstobart + anlotinib vs pembrolizumab in PD-L1+ aNSCLC:
- PFS: 11.0 vs 7.1 mo (HR 0.70)
- ORR: 57.3% vs 39.6%
- Increased toxicity but discontinuation low.
Infographic summary below.”
Other articles featuring Karamvir Yadav on OncoDaily.